Oncolytics Biotech

Contact
oncolyticsbiotech.com
+14036707377

Oncolytics Biotech Inc

210, 1167 Kensington Crescent NW
T2N 1X7 Calgary
Canada
+14036707377
oncolyticsbiotech.com
Contact
Profile Products News
Contact

About Oncolytics Biotech

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.

Read more about Oncolytics Biotech
Facts about Oncolytics Biotech
  • Focus : Manufacturer
  • Industry : Biotechnology

Product portfolio of Oncolytics Biotech

Product portfolio

Show all

Similar companies

Merck Life Science KGaA

Merck Life Science KGaA

Darmstadt
Manufacturer
Laboratory analysis / Laboratory measurement technology
Biotechnology
Search companies
Merck Life Science KGaA

Merck Life Science KGaA

Darmstadt
Manufacturer
Laboratory analysis / Laboratory measurement technology
Biotechnology
Search companies

News about Oncolytics Biotech

Oncolytics Biotech

27-Apr-2010 | research and development

Oncolytics Biotech Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial

Oncolytics Biotech Inc. announced that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) ...

Read news
Oncolytics Biotech

12-Apr-2010 | research and development

Oncolytics Biotech Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy

Oncolytics Biotech Inc. announced that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of ...

Read news
Oncolytics Biotech

15-Dec-2009 | people

Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development

Oncolytics Biotech Inc. announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development. I ...

Read news
Oncolytics Biotech

29-Oct-2009 | research and development

Oncolytics Biotech Inc. Announces Issuance of 33rd U.S. Patent

Oncolytics Biotech Inc. announced that it has been granted its 33rd U.S. Patent, No. 7,608,257, entitled "Sensitization of Chemotherapeutic Agent ...

Read news
Oncolytics Biotech

04-Sep-2008 | research and development

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients

Oncolytics Biotech Inc. announced that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial ...

Read news
Oncolytics Biotech

13-Aug-2008 | research and development

Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN/Docetaxel Trial

Oncolytics Biotech Inc. has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of ...

Read news
Oncolytics Biotech

16-May-2008 | research and development

Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin

Oncolytics Biotech Inc. announced that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) ...

Read news
Oncolytics Biotech

31-Jan-2008 | research and development

Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent

Oncolytics Biotech Inc. has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses ...

Read news
Show more news about Oncolytics Biotech

Here you will find Oncolytics Biotech Inc